



TasP

Antiretroviral Treatment as Prevention - ANRS 12249
(Ukuphila kwami, ukuphila kwethu)

Ukuphila kwami, ukuphila kwethu

Africa Centre TasP Trial

Serious Adverse Event Reporting

ANRS 12249 Initial SAE Notification

SAE-AI



00093290

Completed forms must be sent to
ANRS within 48 hrs.
Email: pharmacovigilance@anrs.fr
Fax: +33 153 946 002

SAE No.

SAE Visit Date

20140429

Initial Notification Date

20140509

Notification time

1. Patient details

TasP ID

26150

Name

T M

Sex

Male

Female

Date of birth

19840509

Enrolment date

20140318

2. Measurements

Height

163

Cms

Last known: Weight

79.9

Kgs

Weight Date

20140429

CD4 count

932

CD4 Date

20140318

Viral Load

<40

Viral Load Date

20140401

3. By which criteria is this adverse event considered to be "Serious"?

Tick all that apply

- ☐ Resulted in death → Date of death Probable cause
- ☐ Life threatening (i.e. at risk of death at time of event)
- ☒ Caused or prolonged hospitalisation (not elective hospitalisation for a pre-existing condition)
- ☐ Persistent or significant disability / incapacity
- ☐ Congenital abnormality / birth defect
- ☐ Grade 4 clinical and biological events
- ☐ Other serious, medically-important condition → Specify



4. Details of SAE

Enter each adverse event (e.g. symptom, sign, syndrome or diagnosis) on a separate line

Event Name

Date investigator
became aware

Date of onset of SAE

1. BREAST 20140506 20140404
ABSCISS

2.

3.

4.

5.

5. Description of SAE

Include details of body site, relevant laboratory tests, treatments received and relevant medical history.


Attach copies of any relevant hospital records, laboratory test results etc.

Admitted to hospital for one day for treatment of breast abscess. Could not remember the day. Was on TDF/FTC/EFV while pregnant. Was discontinued after delivery before she attended/enrolled in TasP clinic. Stopped breast feeding after developing breast abscess.

6. Medications

List all drugs taken (or prescribed) before occurrence of SAE

Generic Name	Daily dose	Route of administration	Indication	Date started	Date stopped	Causality assessment	Expected reaction? (BNF/SPC)	Action taken
1. ATP TDF/FTC/EFV	300/200/600	PO	HW	20140429		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
2.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
3.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
4.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
5.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
6.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop



7. Other causes of SAE, if unrelated to drugs mentioned in Section 6 above

7a. According to the physician, is this SAE likely to be related to participation in the research?

Yes ☐ No ☒

7b. According to the physician, is this SAE related to any causes other than the research?

This includes the patient's medical history

Yes ☒ No ☐

Describe

Complication of breast feeding

8. SAE Outcome

Died

Unknown to date

Ongoing

Improved

→ A complementary SAE notification must be submitted within 8 days

☒ Recovered

→ Date of recovery 20140429

Recovered without sequelae

or

Recovered with sequelae

Describe

Physician reporting SAE

Name

COLLINS / WUJ

Signature

[Signature]

Date form completed

20140509